PubMed:32178765 / 2109-2545 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T16 0-436 Sentence denotes The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p<0·0001).
T16 0-436 Sentence denotes The primary endpoint was met: ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128 [95% CI 50-68]) and every 8 weeks group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks group and 30% (19-41) for the every 8 weeks group (both p<0·0001).

yaoziqian_800_3

Id Subject Object Predicate Lexical cue
T14 116-126 CI denotes guselkumab
T15 242-249 CI denotes placebo
T16 318-325 CI denotes placebo

Zierdiyeerkenaili_800_3

Id Subject Object Predicate Lexical cue
T14 116-126 CI denotes guselkumab
T22 242-249 CI denotes placebo
T23 318-325 CI denotes placebo